Chinese drugmaker Shanghai Pharmaceutical (601607.SS) has confirmed media reports that it is in discussions with financial investors over a possible bid for German generics drugmaker Stada Arzneimittel (SAZ: Xetra).
The firm, which has a market value of $9 billion, added that that there were "a lot of uncertainties" in connection with the offer, saying that earlier reports of a bid of 70 euros ($78) per share were not true.
The Stada board recently indicated it was happy with an offer of 5.3 billion euros ($5.9 billion) to be bought by private-equity companies Bain Capital, from the USA, and London-based Cinven.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze